Real-world use of telavancin in the treatment of osteomyelitis

Louis D. Saravolatz, Kerry Cleveland, Khalid Rikabi, Ali Hassoun, Joseph Reilly, Leonard B. Johnson, Cedric Spak, Sharon Valenti, Susan Szpunar

Research output: Contribution to journalArticle

Abstract

This is a retrospective analysis of patients with osteomyelitis who received telavancin at some time during their treatment course. The primary outcome was the percent of patients cured or improved at the end of telavancin therapy (EOTT). The secondary outcome was the percent of patients cured or improved three months after discontinuation of telavancin therapy. There were 32 cases of osteomyelitis with methicillin-resistant Staphylococcus aureus identified in 17 (56.7%), methicillin-sensitive Staphylococcus aureus 2(6.6%), coagulase negative staphylococci 6 (20.0%) and other pathogens, 5 (16.7%). At EOTT, 87.5% of patients had their osteomyelitis cured and 94.6% had the infection cured at three months after telavancin was completed. The most common adverse events associated with telavancin were gastrointestinal in nature (nausea (25.8%), vomiting (9.7%) and diarrhea (3.2%)) followed by metallic taste (6.5%). A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included telavancin for the treatment of osteomyelitis.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalDiagnostic Microbiology and Infectious Disease
Volume95
Issue number2
DOIs
StatePublished - Oct 1 2019

Fingerprint

Osteomyelitis
Therapeutics
Taste Disorders
Methicillin
Coagulase
Methicillin-Resistant Staphylococcus aureus
telavancin
Staphylococcus
Nausea
Vomiting
Staphylococcus aureus
Diarrhea
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Saravolatz, L. D., Cleveland, K., Rikabi, K., Hassoun, A., Reilly, J., Johnson, L. B., ... Szpunar, S. (2019). Real-world use of telavancin in the treatment of osteomyelitis. Diagnostic Microbiology and Infectious Disease, 95(2), 185-190. https://doi.org/10.1016/j.diagmicrobio.2019.05.011

Real-world use of telavancin in the treatment of osteomyelitis. / Saravolatz, Louis D.; Cleveland, Kerry; Rikabi, Khalid; Hassoun, Ali; Reilly, Joseph; Johnson, Leonard B.; Spak, Cedric; Valenti, Sharon; Szpunar, Susan.

In: Diagnostic Microbiology and Infectious Disease, Vol. 95, No. 2, 01.10.2019, p. 185-190.

Research output: Contribution to journalArticle

Saravolatz, LD, Cleveland, K, Rikabi, K, Hassoun, A, Reilly, J, Johnson, LB, Spak, C, Valenti, S & Szpunar, S 2019, 'Real-world use of telavancin in the treatment of osteomyelitis', Diagnostic Microbiology and Infectious Disease, vol. 95, no. 2, pp. 185-190. https://doi.org/10.1016/j.diagmicrobio.2019.05.011
Saravolatz, Louis D. ; Cleveland, Kerry ; Rikabi, Khalid ; Hassoun, Ali ; Reilly, Joseph ; Johnson, Leonard B. ; Spak, Cedric ; Valenti, Sharon ; Szpunar, Susan. / Real-world use of telavancin in the treatment of osteomyelitis. In: Diagnostic Microbiology and Infectious Disease. 2019 ; Vol. 95, No. 2. pp. 185-190.
@article{fde6323161894636bc0276f850abec68,
title = "Real-world use of telavancin in the treatment of osteomyelitis",
abstract = "This is a retrospective analysis of patients with osteomyelitis who received telavancin at some time during their treatment course. The primary outcome was the percent of patients cured or improved at the end of telavancin therapy (EOTT). The secondary outcome was the percent of patients cured or improved three months after discontinuation of telavancin therapy. There were 32 cases of osteomyelitis with methicillin-resistant Staphylococcus aureus identified in 17 (56.7{\%}), methicillin-sensitive Staphylococcus aureus 2(6.6{\%}), coagulase negative staphylococci 6 (20.0{\%}) and other pathogens, 5 (16.7{\%}). At EOTT, 87.5{\%} of patients had their osteomyelitis cured and 94.6{\%} had the infection cured at three months after telavancin was completed. The most common adverse events associated with telavancin were gastrointestinal in nature (nausea (25.8{\%}), vomiting (9.7{\%}) and diarrhea (3.2{\%})) followed by metallic taste (6.5{\%}). A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included telavancin for the treatment of osteomyelitis.",
author = "Saravolatz, {Louis D.} and Kerry Cleveland and Khalid Rikabi and Ali Hassoun and Joseph Reilly and Johnson, {Leonard B.} and Cedric Spak and Sharon Valenti and Susan Szpunar",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.diagmicrobio.2019.05.011",
language = "English (US)",
volume = "95",
pages = "185--190",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Real-world use of telavancin in the treatment of osteomyelitis

AU - Saravolatz, Louis D.

AU - Cleveland, Kerry

AU - Rikabi, Khalid

AU - Hassoun, Ali

AU - Reilly, Joseph

AU - Johnson, Leonard B.

AU - Spak, Cedric

AU - Valenti, Sharon

AU - Szpunar, Susan

PY - 2019/10/1

Y1 - 2019/10/1

N2 - This is a retrospective analysis of patients with osteomyelitis who received telavancin at some time during their treatment course. The primary outcome was the percent of patients cured or improved at the end of telavancin therapy (EOTT). The secondary outcome was the percent of patients cured or improved three months after discontinuation of telavancin therapy. There were 32 cases of osteomyelitis with methicillin-resistant Staphylococcus aureus identified in 17 (56.7%), methicillin-sensitive Staphylococcus aureus 2(6.6%), coagulase negative staphylococci 6 (20.0%) and other pathogens, 5 (16.7%). At EOTT, 87.5% of patients had their osteomyelitis cured and 94.6% had the infection cured at three months after telavancin was completed. The most common adverse events associated with telavancin were gastrointestinal in nature (nausea (25.8%), vomiting (9.7%) and diarrhea (3.2%)) followed by metallic taste (6.5%). A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included telavancin for the treatment of osteomyelitis.

AB - This is a retrospective analysis of patients with osteomyelitis who received telavancin at some time during their treatment course. The primary outcome was the percent of patients cured or improved at the end of telavancin therapy (EOTT). The secondary outcome was the percent of patients cured or improved three months after discontinuation of telavancin therapy. There were 32 cases of osteomyelitis with methicillin-resistant Staphylococcus aureus identified in 17 (56.7%), methicillin-sensitive Staphylococcus aureus 2(6.6%), coagulase negative staphylococci 6 (20.0%) and other pathogens, 5 (16.7%). At EOTT, 87.5% of patients had their osteomyelitis cured and 94.6% had the infection cured at three months after telavancin was completed. The most common adverse events associated with telavancin were gastrointestinal in nature (nausea (25.8%), vomiting (9.7%) and diarrhea (3.2%)) followed by metallic taste (6.5%). A favorable outcome was achieved for many patients receiving the antimicrobial regimen that included telavancin for the treatment of osteomyelitis.

UR - http://www.scopus.com/inward/record.url?scp=85067863591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067863591&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2019.05.011

DO - 10.1016/j.diagmicrobio.2019.05.011

M3 - Article

VL - 95

SP - 185

EP - 190

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 2

ER -